Synonyms: Camzyos® | MYK-461 | MYK461
mavacamten is an approved drug (FDA (2022), EMA (2023))
Compound class:
Synthetic organic
Comment: Mavacamten (MYK-461) is an orally active myosin allosteric modulator [1] that was developed by MyoKardia as a novel treatment for obstructive hypertrophic cardiomyopathy (HCM). In 2020 MyoKardia was bought by Bristol Myers Squibb. The compound interacts with both α and β cardiac myosins in vitro. Preclinical pharmacokinetics are reported in [2]. Mavacamten attenuates hypertrophic and profibrotic gene expression in rodent models of HCM [1].
|
|
Bioactivity Comments |
In experiments using mouse cardiac myofibrils mavacamten (MYK-461) dose-dependently reduces ATPase activity, with an IC50 of 300 nM [1]. |